Navigating Barriers to Treatment for Hepatitis C Virus Infection in Primary Care Settings
Thursday, June 14, 2018
Summary: Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) that produces liver inflammation and damage. In 2014, a total of 2,194 cases of acute hepatitis C were reported to CDC from 40 states. In the United States, hepatitis C virus (HCV) infection is a leading cause of liver-related deaths, cirrhosis, liver cancer. The advent of direct-acting antivirals (DAAs) to combat Hepatitis C (HCV) is a major development in curing the deadliest infectious disease in the United States. Unfortunately, despite the important individual and public health potential of these medications many public and private payers choose to limit access to DAAs due to their cost as well as other concerns. This webinar will outline the financial impact of hepatitis C virus on US healthcare, common restrictions of HCV treatment among payers and the successful acquisition of DAA therapy